Clinical trial
A Phase 2, Randomized, Double-blind, Multi-center, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-497
NCT03726853 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Multi-center, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-497
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 29, 2018
- Completion date
- March 21, 2019
- Enrollment
- 220 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
respiratory infection